Preservative-free therapy for glaucoma after corneal refractive surgery

А.А. Antonov¹, I.V. Kozlova¹, T.S. Mitichkina¹, I.I. Vedmedenko²

¹Scientific Research Insitute of Eye Diseases, Moscow, Russian Federation

²Sechenov University, Moscow, Russian Federation

Corneal refractive surgery is now a common technique to improve the quality of life. In addition to classical issues and difficulties, this results in the reduced quality of glaucoma screening and monitoring in a complex group with myopic refraction at baseline. In patients who underwent corneal refractive surgery corneal shape depends on the intraocular pressure (IOP) greater than in patients with intact fibrous tunic. Moreover, its biomechanic properties are more diverse. As a result of an increased percentage of these patients and their aging, glaucoma is diagnosed more often in this group. In these patients, glaucoma is a specific condition because of low significance of classical screening and diagnostic tools. IOP-lowering treatment should not affect ocular surface but provide a stable IOP level. Diagnostic and treatment modalities for refractive disorders are promising for broad clinical application. Preservative-free prostaglandin analogue, tafluprost, is a novel IOP-l owering therapeutic agent to prescribe after corneal refractive surgery.

Keywords: glaucoma, refractive surgery, radial keratotomy, intraocular pressure, tonometry, progressive hyperopia, preservative-free therapy, timolol.

For citation: Antonov А.А., Kozlova I.V., Mitichkina T.S., Vedmedenko I.I. Preservative-free therapy for glaucoma after corneal refractive surgery. Russian Journal of Clinical Ophthalmology. 2019;19(3):165–169.